Literature DB >> 30135306

Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma.

Anshuman Panda1,2, Aguirre A de Cubas3, Mark Stein1,4, Gregory Riedlinger1, Joshua Kra1, Tina Mayer1, Christof C Smith5, Benjamin G Vincent5, Jonathan S Serody5, Kathryn E Beckermann3,6, Shridar Ganesan1,4, Gyan Bhanot1,2,7, W Kimryn Rathmell3,6.   

Abstract

Although a subset of clear cell renal cell carcinoma (ccRCC) patients respond to immune checkpoint blockade (ICB), predictors of response remain uncertain. We investigated whether abnormal expression of endogenous retroviruses (ERVs) in tumors is associated with local immune checkpoint activation (ICA) and response to ICB. Twenty potentially immunogenic ERVs (πERVs) were identified in ccRCC in The Cancer Genome Atlas data set, and tumors were stratified into 3 groups based on their expression levels. πERV-high ccRCC tumors showed increased immune infiltration, checkpoint pathway upregulation, and higher CD8+ T cell fraction in infiltrating leukocytes compared with πERV-low ccRCC tumors. Similar results were observed in ER+/HER2- breast, colon, and head and neck squamous cell cancers. ERV expression correlated with expression of genes associated with histone methylation and chromatin regulation, and πERV-high ccRCC was enriched in BAP1 mutant tumors. ERV3-2 expression correlated with ICA in 11 solid cancers, including the 4 named above. In a small retrospective cohort of 24 metastatic ccRCC patients treated with single-agent PD-1/PD-L1 blockade, ERV3-2 expression in tumors was significantly higher in responders compared with nonresponders. Thus, abnormal expression of πERVs is associated with ICA in several solid cancers, including ccRCC, and ERV3-2 expression is associated with response to ICB in ccRCC.

Entities:  

Keywords:  Immunology; Immunotherapy; Oncology

Year:  2018        PMID: 30135306      PMCID: PMC6141170          DOI: 10.1172/jci.insight.121522

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  30 in total

1.  Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

Authors:  Diana Miao; Claire A Margolis; Wenhua Gao; Martin H Voss; Wei Li; Dylan J Martini; Craig Norton; Dominick Bossé; Stephanie M Wankowicz; Dana Cullen; Christine Horak; Megan Wind-Rotolo; Adam Tracy; Marios Giannakis; Frank Stephen Hodi; Charles G Drake; Mark W Ball; Mohamad E Allaf; Alexandra Snyder; Matthew D Hellmann; Thai Ho; Robert J Motzer; Sabina Signoretti; William G Kaelin; Toni K Choueiri; Eliezer M Van Allen
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728

2.  Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.

Authors:  Janice M Mehnert; Anshuman Panda; Hua Zhong; Kim Hirshfield; Sherri Damare; Katherine Lane; Levi Sokol; Mark N Stein; Lorna Rodriguez-Rodriquez; Howard L Kaufman; Siraj Ali; Jeffrey S Ross; Dean C Pavlick; Gyan Bhanot; Eileen P White; Robert S DiPaola; Ann Lovell; Jonathan Cheng; Shridar Ganesan
Journal:  J Clin Invest       Date:  2016-05-09       Impact factor: 14.808

Review 3.  Prospects for targeting PD-1 and PD-L1 in various tumor types.

Authors:  Joseph W Kim; Joseph Paul Eder
Journal:  Oncology (Williston Park)       Date:  2014-11       Impact factor: 2.990

4.  Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Authors:  Howard L Kaufman; Jeffery Russell; Omid Hamid; Shailender Bhatia; Patrick Terheyden; Sandra P D'Angelo; Kent C Shih; Céleste Lebbé; Gerald P Linette; Michele Milella; Isaac Brownell; Karl D Lewis; Jochen H Lorch; Kevin Chin; Lisa Mahnke; Anja von Heydebreck; Jean-Marie Cuillerot; Paul Nghiem
Journal:  Lancet Oncol       Date:  2016-09-01       Impact factor: 41.316

5.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

6.  PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Authors:  Paul T Nghiem; Shailender Bhatia; Evan J Lipson; Ragini R Kudchadkar; Natalie J Miller; Lakshmanan Annamalai; Sneha Berry; Elliot K Chartash; Adil Daud; Steven P Fling; Philip A Friedlander; Harriet M Kluger; Holbrook E Kohrt; Lisa Lundgren; Kim Margolin; Alan Mitchell; Thomas Olencki; Drew M Pardoll; Sunil A Reddy; Erica M Shantha; William H Sharfman; Elad Sharon; Lynn R Shemanski; Michi M Shinohara; Joel C Sunshine; Janis M Taube; John A Thompson; Steven M Townson; Jennifer H Yearley; Suzanne L Topalian; Martin A Cheever
Journal:  N Engl J Med       Date:  2016-04-19       Impact factor: 91.245

7.  Identification of human endogenous retroviruses with complex mRNA expression and particle formation.

Authors:  R Löwer; K Boller; B Hasenmaier; C Korbmacher; N Müller-Lantzsch; J Löwer; R Kurth
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

8.  Inferring tumour purity and stromal and immune cell admixture from expression data.

Authors:  Kosuke Yoshihara; Maria Shahmoradgoli; Emmanuel Martínez; Rahulsimham Vegesna; Hoon Kim; Wandaliz Torres-Garcia; Victor Treviño; Hui Shen; Peter W Laird; Douglas A Levine; Scott L Carter; Gad Getz; Katherine Stemke-Hale; Gordon B Mills; Roel G W Verhaak
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  ToppGene Suite for gene list enrichment analysis and candidate gene prioritization.

Authors:  Jing Chen; Eric E Bardes; Bruce J Aronow; Anil G Jegga
Journal:  Nucleic Acids Res       Date:  2009-05-22       Impact factor: 16.971

10.  Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors.

Authors:  Anshuman Panda; Anil Betigeri; Kalyanasundaram Subramanian; Jeffrey S Ross; Dean C Pavlick; Siraj Ali; Paul Markowski; Ann Silk; Howard L Kaufman; Edmund Lattime; Janice M Mehnert; Ryan Sullivan; Christine M Lovly; Jeffrey Sosman; Douglas B Johnson; Gyan Bhanot; Shridar Ganesan
Journal:  JCO Precis Oncol       Date:  2017-12-07
View more
  60 in total

Review 1.  Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.

Authors:  Vid Leko; Steven A Rosenberg
Journal:  Cancer Cell       Date:  2020-08-20       Impact factor: 31.743

Review 2.  Genomic correlates of response to immune checkpoint blockade.

Authors:  Tanya E Keenan; Kelly P Burke; Eliezer M Van Allen
Journal:  Nat Med       Date:  2019-03-06       Impact factor: 53.440

3.  Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.

Authors:  Sabina Signoretti; Catherine J Wu; Sachet A Shukla; Toni K Choueiri; David A Braun; Yue Hou; Ziad Bakouny; Miriam Ficial; Miriam Sant' Angelo; Juliet Forman; Petra Ross-Macdonald; Ashton C Berger; Opeyemi A Jegede; Liudmilla Elagina; John Steinharter; Maxine Sun; Megan Wind-Rotolo; Jean-Christophe Pignon; Andrew D Cherniack; Lee Lichtenstein; Donna Neuberg; Paul Catalano; Gordon J Freeman; Arlene H Sharpe; David F McDermott; Eliezer M Van Allen
Journal:  Nat Med       Date:  2020-05-29       Impact factor: 53.440

Review 4.  The evolving role of cytoreductive nephrectomy: incorporating genomics of metastatic renal cell carcinoma into treatment decisions.

Authors:  Roy Mano; Nikhil Gopal; A Ari Hakimi
Journal:  Curr Opin Urol       Date:  2019-09       Impact factor: 2.309

5.  Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.

Authors:  Lewis Au; Emine Hatipoglu; Marc Robert de Massy; Kevin Litchfield; Gordon Beattie; Andrew Rowan; Desiree Schnidrig; Rachael Thompson; Fiona Byrne; Stuart Horswell; Nicos Fotiadis; Steve Hazell; David Nicol; Scott T C Shepherd; Annika Fendler; Robert Mason; Lyra Del Rosario; Kim Edmonds; Karla Lingard; Sarah Sarker; Mary Mangwende; Eleanor Carlyle; Jan Attig; Kroopa Joshi; Imran Uddin; Pablo D Becker; Mariana Werner Sunderland; Ayse Akarca; Ignazio Puccio; William W Yang; Tom Lund; Kim Dhillon; Marcos Duran Vasquez; Ehsan Ghorani; Hang Xu; Charlotte Spencer; José I López; Anna Green; Ula Mahadeva; Elaine Borg; Miriam Mitchison; David A Moore; Ian Proctor; Mary Falzon; Lisa Pickering; Andrew J S Furness; James L Reading; Roberto Salgado; Teresa Marafioti; Mariam Jamal-Hanjani; George Kassiotis; Benny Chain; James Larkin; Charles Swanton; Sergio A Quezada; Samra Turajlic
Journal:  Cancer Cell       Date:  2021-10-28       Impact factor: 31.743

6.  Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.

Authors:  David J Clark; Saravana M Dhanasekaran; Francesca Petralia; Jianbo Pan; Xiaoyu Song; Yingwei Hu; Felipe da Veiga Leprevost; Boris Reva; Tung-Shing M Lih; Hui-Yin Chang; Weiping Ma; Chen Huang; Christopher J Ricketts; Lijun Chen; Azra Krek; Yize Li; Dmitry Rykunov; Qing Kay Li; Lin S Chen; Umut Ozbek; Suhas Vasaikar; Yige Wu; Seungyeul Yoo; Shrabanti Chowdhury; Matthew A Wyczalkowski; Jiayi Ji; Michael Schnaubelt; Andy Kong; Sunantha Sethuraman; Dmitry M Avtonomov; Minghui Ao; Antonio Colaprico; Song Cao; Kyung-Cho Cho; Selim Kalayci; Shiyong Ma; Wenke Liu; Kelly Ruggles; Anna Calinawan; Zeynep H Gümüş; Daniel Geiszler; Emily Kawaler; Guo Ci Teo; Bo Wen; Yuping Zhang; Sarah Keegan; Kai Li; Feng Chen; Nathan Edwards; Phillip M Pierorazio; Xi Steven Chen; Christian P Pavlovich; A Ari Hakimi; Gabriel Brominski; James J Hsieh; Andrzej Antczak; Tatiana Omelchenko; Jan Lubinski; Maciej Wiznerowicz; W Marston Linehan; Christopher R Kinsinger; Mathangi Thiagarajan; Emily S Boja; Mehdi Mesri; Tara Hiltke; Ana I Robles; Henry Rodriguez; Jiang Qian; David Fenyö; Bing Zhang; Li Ding; Eric Schadt; Arul M Chinnaiyan; Zhen Zhang; Gilbert S Omenn; Marcin Cieslik; Daniel W Chan; Alexey I Nesvizhskii; Pei Wang; Hui Zhang
Journal:  Cell       Date:  2019-10-31       Impact factor: 41.582

Review 7.  Alternative tumour-specific antigens.

Authors:  Christof C Smith; Sara R Selitsky; Shengjie Chai; Paul M Armistead; Benjamin G Vincent; Jonathan S Serody
Journal:  Nat Rev Cancer       Date:  2019-07-05       Impact factor: 60.716

Review 8.  Leveraging epigenetics to enhance the efficacy of immunotherapy.

Authors:  Jonathan D Licht; Richard L Bennett
Journal:  Clin Epigenetics       Date:  2021-05-17       Impact factor: 6.551

9.  Alterations, Interactions, and Diagnostic Potential of Gut Bacteria and Viruses in Colorectal Cancer.

Authors:  Renyuan Gao; Yefei Zhu; Cheng Kong; Kai Xia; Hao Li; Yin Zhu; Xiaohui Zhang; Yongqiang Liu; Hui Zhong; Rong Yang; Chunqiu Chen; Nan Qin; Huanlong Qin
Journal:  Front Cell Infect Microbiol       Date:  2021-07-06       Impact factor: 5.293

10.  Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma.

Authors:  Miriam Ficial; Opeyemi A Jegede; Miriam Sant'Angelo; Yue Hou; Abdallah Flaifel; Jean-Christophe Pignon; David A Braun; Megan Wind-Rotolo; Maura A Sticco-Ivins; Paul J Catalano; Gordon J Freeman; Arlene H Sharpe; F Stephen Hodi; Robert J Motzer; Catherine J Wu; Michael B Atkins; David F McDermott; Sachet A Shukla; Toni K Choueiri; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2020-11-20       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.